Sufentanil (sufentanil citrate) has been marketed in China since 2003. It has greater analgesic potency and a superior safety profile as compared to other fentanil derivatives.
Sufentanil is indicated for:
- Anesthesia during procedures including endotracheal intubation for artificial respiration.
- As an analgesic component of combination anesthesia.
- For the induction and maintenance of general anesthesia in major operations.
|